Citation: Uhrikova I, Sepsi M, Hlozkova J, Suchy P, Kasajova M, Machackova K, Delev DP, Ciccocioppo R, Kruzliak P, Scheer P Changes in Hematologic and coagulation profi les in rabbits with right-ventricle pacing.
INTRODUCTION
Placement of a permanent pacemaker in humans is associated with a number of clinical and laboratory fi ndings such as pre-thrombotic state 1 , clot formation on electric leads 2 or thrombosis 3, 4 , whilst other studies did not confi rm the presence of thrombosis in patients with pacemaker 5 . Pacemaker placement is common also in veterinary medicine, mainly in dogs and cats 6, 7 , and thrombotic complications in the latter have been described as well 8 . However, it is not clear if the common cause of these complications is a primary cardiac disease, the foreign material in the heart and vessels or a combination of both.
Rabbits are frequently used as laboratory animals, mainly due to easy manipulation and adequate size. Moreover, by considering that the coagulation system of each animal is different, it is worth noting that rabbits are routinely used as model animals for evaluation of hemostasis. The most common studies are about thrombotic disorders, because rabbits' platelet function is similar to that in humans. [9] [10] [11] Up to date, the hematologic or coagulation changes in rabbits with right-ventricle pacing have not yet been studied. The aim of this study, therefore, was to compare the changes in hematology and coagulation in healthy rabbits before and after permanent transvenous right-ventricle pacing for evaluation of pure pacemaker presence on hemostasis.
MATERIAL AND METHODS

ANIMALS
Ten clinically healthy New Zealand white rabbits (albino) were used in this study. They were all males with an average weight of 3.1 kg (range 2.9-3.3 kg) and age of 14 weeks. The rabbits were vaccinated against myxomatosis and plague (Pestorin Mormyx Bioveta a.s., Ivanovice na Hane, Czech Republic) two weeks prior to first blood collection. The animals were kept in metal cages (50×60×70 cm) during the experiment. The cages were situated in a room with a temperature of 19±1°C and relative air humidity between 55 and 60%. The complete feed mixture (Biostan KV, Biosta Blučina, Czech Republic) and drinking water were administered ad libitum. A natural light regimen was maintained, health condition was checked daily.
After a period of adaptation (4 weeks), the rabbits underwent anesthesia and a right-ventricle pacemaker was placed in all animals. Due to the anatomical situation in this breed, implantations of pacemaker were done through the vena jugularis externa sinistra. Induction to anesthesia was performed using diazepam (2 mg/kg b.w., i.m., Apaurin inj., KRKA d.d. Novo mesto, Slovenia), ketamine (35 mg/kg b.w., i.m., Narketan 100 mg/mL inj., Vétoquinol s.r.o. Nymburk, Czech Republic) and xylazine (5 mg/ kg b.w., i.m., Xylapan 20 mg/mL inj., Vétoquinol s.r.o. Nymburk, Czech Republic). Basal anesthesia was maintained using 0.5-1.5% mixture of oxygen and isofl urane (Aerrane, Baxter Manufacturing Sp. z o.o., Lublin, Poland). Infusion therapy was maintained through the auricular vein. After a close shave of ventricular part of the neck, place for pacemaker in front of musculus suprascapularis and thorax, ultrasonography for exclusion of inherited heart disease was performed. The animal was positioned on its right side; vena jugularis externa sinistra was prepared. Ligation of cranial branches of v. jugularis externa sinistra was performed, on caudal pole two strands were used for fi xation of electrode in the vessel. The electrode with active fi xation (Tendril ST 1888TC/52 cm, St. Jude Medical, Minnesota, US) was placed in right ventricle and then fi xated in the vessel. A pocket for pacemaker was prepared in suprascapular region and pacemaker (Sustain XL SC 1134, Verity XL SC 5056, Sustain XL SR 1136 or Sustain XL DC 2134, St. Jude Medical, Minnesota, US) was connected to the electrode. After suture, pacemaker with blinded atrial port was checked and set to stimulation 170/min (physiologic for rabbits), ejection 3.5V/0.4 msec, sensitivity based on R wave 0.1 mV. After surgery, rabbits received marbofl oxacin (2 mg/kg, s.c./48 hours) and tolfenamic acid (4 mg/kg b.w., s.c./48 hours) for 7 days. BLOOD COLLECTION Blood samples were harvested one day before and one month after pacemaker placement from the vena jugularis externa and collected into citrate and EDTA (Dispolab s.r.o., Brno, Czech Republic) test tubes. Hematologic examination (measurement of total erythrocyte, leukocyte and platelet count, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration and differential leukocyte count) was performed from EDTA blood samples on automated hematologic analyzer (Sysmex XT 2000iV, Sysmex Corporation, Kobe, Japan) within 10 minutes. One milliliter of citrated blood was separated for kaolin-activated thromboelastography (TEG, TEG ® 5000 Thromboelastograph ® Hemostasis System, Hemoscope Corporation, Illinois, USA) and the rest of the blood sample was centrifuged (1000 g, 10 min) and used for coagulation analysis. STATISTICAL ANALYSIS Data were statistically analysed (MedCalc bvba, Ostend, Belgium). Both the hematologic and coagulation parameters (before and after pacemaker placement) were compared using the Wilcoxon paired test with a signifi cance level set at p<0.05.
RESULTS
Signifi cant differences were found in erythrocyte count, hematocrit, hemoglobin and platelet count before and after pacemaker placement (Table 1) . After pacemaker insertion, a signifi cant increase in erythrocytes, hemoglobin and hematocrit and drop in platelet count was observed.
Results from coagulation tests are listed in Table 2. There were no signifi cant differences in the routine coagulation parameters and kaolin-induced thromboelastography before and after pacemaker insertion.
DISCUSSION
Pacemaker placement in human medicine is often connected with anticoagulant or antiplatelet medication. This is why a prethrombotic state has been demonstrated in patients with long-term transvenous pacing even without evident thrombosis. 1 Moreover, another work focused on clot formation on cardiac device leads demonstrated that thrombi development is signifi cantly associated with atrial fi brillation. Among patients with clot formation, 20% did not receive anticoagulant/antiplatelet therapy, 40% received antiplatelet therapy, 13% received anticoagulant therapy, 27% received both antiplatelet and anticoagulant therapy. 2 Since 2009, we have performed 25 successful pacemaker placements in dogs and one cat with no need of further anticoagulant or antiplatelet medication. Thus, we were wondering if there were any changes in hematologic and coagulation profi le caused by pure pacemaker implantation. We have chosen rabbits as model animal due to easy manipulation, standardized procedure and relatively large size of lead in comparison to the body.
The hematologic exams before pacing were similar to those previously published for rabbits. 12, 13 Furthermore, we found a lower range of the mean corpuscular volume (MCV) in comparison to that reported by Marshall et al. 12 , and higher erythrocyte and leukocyte counts, with a high number of neutrophils, monocytes and lymphocytes, but lower eosinophils with respect to data from Jeklova et al 13 . Basophil count was very similar. The reason for this discrepancy may lie in holding conditions, since our rabbits were kept in the conventional system and those of Jeklova et al. 13 in specifi cpathogen-free system. After pacemaker placement, a signifi cant increase in red blood cell count, hemoglobin and hematocrit was observed. The most probable reason of this increase was an elevation in red blood cell mass due to the growth of the animals as was described previously 12 since the second blood sampling was harvested one month after the fi rst sampling (median weight 3.1 kg vs. 3.5 kg). The decrease in platelet count could indicate an increased consumption; however, a further test does not confi rm the hypercoagulability state, and both median platelet counts were within reference range published for New Zealand rabbits. 14 As far as the coagulation tests are concerned, prothrombin time and aPTT were similar to those previously published, whilst thrombin time was shorter and fi brinogen level lower than those reported by Mochizuki et al. 15 Results from thromboelastography differed from previously published results. 16 Indeed, reaction time (R-time) and speed of clot formation (K-time) were longer in our study and α angle was lower indicating generally slower clot formation. Difference between studies may be due to the different protocols used: Shimokawa et al. 16 collected blood from anesthetized animals whilst we did not use any medication prior to blood collection, and it is not clear what type of activator they used for measurement. In addition, we performed our study only on male rabbits, whereas in the mentioned study only female animals were used. 16 To our best knowledge, this is the fi rst study reporting kaolin-activated thromboelastography in rabbits. The signifi cant infl uence of gender on thromboelastography results has been repeatedly proven in humans with the same pattern, where males had higher values of R-time, K-time and lower values for α angle and MA. 17, 18 After rightventricle pacing, there were no signifi cant changes in coagulation tests indicating that placement of a pacemaker in rabbits was probably not associated with hypocoagulability or hypercoagulability at the time of measurement. Fibrinogen concentration and thrombin time were slightly increased, but interference with fi brinogen degradation products (FDP) seems to be ruled out because levels of D-dimers were low. Also, FDP does not increase fi brinogen levels in rabbits. 19 In conclusion, the results of this study indicate that pure insertion of pacemaker is not associated with hematologic and coagulation changes and then anticoagulant and antiplatelet medication is not needed. 
